Asunto(s)
Acidosis Tubular Renal/genética , Proteínas de Transporte de Anión , Antiportadores , Proteínas Portadoras/genética , Anomalías del Ojo/genética , Proteínas de la Membrana/genética , Proteínas de la Membrana/fisiología , Mutación , Acidosis Tubular Renal/patología , Acidosis Tubular Renal/fisiopatología , Adolescente , Adulto , Sustitución de Aminoácidos , Ceguera , Proteínas Portadoras/fisiología , Preescolar , Cromosomas Humanos Par 4/genética , Consanguinidad , Análisis Mutacional de ADN , Anomalías del Ojo/fisiopatología , Femenino , Homocigoto , Humanos , Riñón/metabolismo , Riñón/patología , Masculino , Proteínas SLC4A , Simportadores de Sodio-BicarbonatoRESUMEN
Saireito, a saiko agent (a Chinese herbal drug), increases the synthesis and secretion of ACTH by stimulating hypothalamic CRH release. In the present study, we examined the effect of food containing saireito (1.5%) on the recovery of the hypothalamic-pituitary-adrenal axis after treating male rats with prednisolone (PSL, 200 microM) in drinking water for 14 days. Saireito was administered during and after PSL administration. The rats were decapitated at various times after PSL administration. Tail-pinch stress had been applied to some rats. The plasma ACTH response to tail-pinch stress in the PSL + saireito group recovered to the control level on day 1, but that in the group given PSL alone recovered on day 3. The ACTH level in the anterior pituitary and the CRH level in the median eminence of the PSL + saireito group returned to the control level on day 3, and that in the group given PSL alone returned to it on day 5. These results indicate that the administration of saireito reduces the negative feedback effect of PSL on the hypothalamus and pituitary and accelerates the recovery of the hypothalamic CRH and pituitary ACTH level after glucocorticoid treatment.
Asunto(s)
Enfermedades de las Glándulas Suprarrenales/tratamiento farmacológico , Medicamentos Herbarios Chinos/farmacología , Enfermedades Hipotalámicas/tratamiento farmacológico , Enfermedades de la Hipófisis/tratamiento farmacológico , Prednisolona/toxicidad , Enfermedades de las Glándulas Suprarrenales/inducido químicamente , Hormona Adrenocorticotrópica/sangre , Hormona Adrenocorticotrópica/metabolismo , Animales , Peso Corporal , Hormona Liberadora de Corticotropina/metabolismo , Enfermedades Hipotalámicas/inducido químicamente , Cinética , Masculino , Eminencia Media/metabolismo , Enfermedades de la Hipófisis/inducido químicamente , Adenohipófisis/metabolismo , Ratas , Ratas Wistar , Estrés Fisiológico/sangreRESUMEN
We examined the affinity of endothelin-1, endothelin-3 and four endothelin receptor ligands, BQ788 (cis-2,6-dimethylpiperidinocarbonyl-gamma-methyl-Leu-D-Trp(1-CO 2CH3-D-Nle-ONa), SB-209670 ((+)-(1S,2R,3S)-3-(2-carboxymethoxy-4-methoxyphenyl)-1-(3,4-methylenedio xyphenyl)-5-(prop-1-yloxy)indane-2-carboxylic acid), IRL-1620 (succinyl-[Glu9,Ala11,15]endothelin-1(8-21)), and L-749329 (3',4'-methylenedioxy-1-(2-propyl-4-carboxyphenoxy)-N-(4-isopropyl -phenylsulfonyl)-benzene acetamide), for endothelin ET(B) receptors in human and rat heart cells. The affinities of these ligands showed good correlation between both types of living cells and between their membrane preparations (r = 0.861, P < 0.001), but less significant correlation between each of the living cells and its respective membrane preparation (r = 0.569, 0.02 < P < 0.05). These results suggest that there is no species difference in the affinities of these ligands and that destruction of the intact cell membrane structure may lead to changes in binding properties of the endothelin ET(B) receptor.
Asunto(s)
Membrana Celular/metabolismo , Receptores de Endotelina/metabolismo , Animales , Animales Recién Nacidos , Membrana Celular/efectos de los fármacos , Células Cultivadas , Endotelina-2/metabolismo , Humanos , Técnicas In Vitro , Radioisótopos de Yodo , Ligandos , Masculino , Miocardio/citología , Miocardio/metabolismo , Ratas , Ratas Wistar , Receptor de Endotelina B , Receptores de Endotelina/efectos de los fármacosRESUMEN
To examine the direct effects of serotonin (5-HT) on the release and synthesis of corticotropin-releasing factor (CRF) in the hypothalamic paraventricular nucleus (PVN), 5-HT was microinjected just onto the bilateral PVN of conscious rats. Plasma adrenocorticotropic hormone (ACTH) levels peaked at 30 min and returned to the basal levels in 90 min. Northern blot analysis revealed that the CRF messenger RNA (mRNA) level in the PVN as well as the proopiomelanocortin mRNA level in the anterior pituitary significantly increased 120 min after the 5-HT injections (50-250 nmol/side). Pretreatment with intracerebroventricular (i.c.v.) injection of pindobind 5-HT1A (5 nmol) or LY-278584 (500 nmol) completely abolished the 5-HT-induced ACTH response, whereas LY-53857 (100 nmol) was without effect. These results suggest that 5-HT stimulates CRF release, which has interactions with 5-HT1A and 5-HT3 receptors on CRF neurons in the PVN, and activates CRF synthesis in conscious rats.
Asunto(s)
Hormona Liberadora de Corticotropina/genética , Núcleo Hipotalámico Paraventricular/fisiología , Serotonina/farmacología , Hormona Adrenocorticotrópica/metabolismo , Animales , Northern Blotting , Estado de Conciencia , Monoterpenos Ciclohexánicos , Relación Dosis-Respuesta a Droga , Ergolinas/farmacología , Expresión Génica/efectos de los fármacos , Masculino , Microinyecciones , Neuronas/química , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Núcleo Hipotalámico Paraventricular/citología , Núcleo Hipotalámico Paraventricular/efectos de los fármacos , Pindolol/análogos & derivados , Pindolol/farmacología , Proopiomelanocortina/metabolismo , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Receptores de Serotonina/fisiología , Receptores de Serotonina 5-HT1 , Antagonistas de la Serotonina/farmacologíaRESUMEN
S-0139 (27-O-3-[2-(3-carboxy-acryloylamino)-5-hydroxyphenyl]-acryloylo xy myricerone, sodium salt) is a highly specific nonpeptide endothelin ET(A) receptor antagonist. The binding of [3H]S-0139 was compared to that of [125I]endothelin-1 to characterize the binding of the antagonist in porcine aortic smooth muscle membranes. Scatchard analysis revealed a single class of [3H]S-0139 binding sites with a Kd value of 0.61 +/- 0.10 nM and a Bmax of 0.72 +/- 0.16 pmol/mg protein. These sites were saturable and reversible. [125I]Endothelin-1 also showed binding with high affinity (Kd = 0.12 +/- 0.02 nM) to a homogeneous population of binding sites, whose Bmax (0.71 +/- 0.20 pmol/mg protein) was almost the same as that for [3H]S-0139. In both cases, the binding could be displaced by known endothelin receptor ligands and their IC50 values in each case showed a very close correlation (r = 0.986). The potency of seven endothelin receptor antagonists to displace [3H]S-0139 binding also correlated highly to the potency for inhibiting the endothelin-1-induced increase in cytosolic Ca2+ concentration (r = 0.949). Myriceric acid A showed a more potent functional activity than expected from its binding affinity, but this seemed to result from the different assay conditions, such as incubation time. Together, the results suggest that S-0139 labels only endothelin ET(A) receptor binding sites in porcine aortic smooth muscle.
Asunto(s)
Ácidos Cafeicos/metabolismo , Antagonistas de los Receptores de Endotelina , Músculo Liso Vascular/metabolismo , Ácido Oleanólico/análogos & derivados , Animales , Aorta Torácica/metabolismo , Calcio/metabolismo , Citosol/metabolismo , Endotelinas/metabolismo , Técnicas In Vitro , Radioisótopos de Yodo , Ácido Oleanólico/metabolismo , Porcinos , Triterpenos/metabolismoRESUMEN
To investigate the expression of CRF receptor (CRF-R) in human corticotropic adenoma (hCA) cells, we analyzed messenger RNA (mRNA) levels of type-1 CRF-R (CRF-R1). Adenomas were obtained from 10 patients with Cushing's disease. Northern blot analysis using a rat CRF-R1 complementary RNA probe revealed a main hybridization band of 2.7 kilobases in all the hCAs. The CRF-R1 mRNA level significantly increased after 1 h, reached 15-fold the basal level at 8 h, and remained elevated 24 h after the addition of 10 nmol/L CRF in vitro. Dose dependency of the stimulatory effect of CRF was also demonstrated in hCA cells, whereas CRF down-regulated CRF-R1 mRNA levels in rat anterior pituitary (AP) cells. Treatment with dexamethasone or vasopressin decreased the CRF-R1 mRNA level in hCA cells, as observed in rat AP cells. In conclusion, we detected CRF-R1 mRNA in all hCAs tested. The CRF-R1 mRNA level was up-regulated by CRF itself in cultured hCA cells, in contrast to the down-regulation in rat AP cells.
Asunto(s)
Adenoma/genética , Hormona Adrenocorticotrópica/metabolismo , Hormona Liberadora de Corticotropina/farmacología , Expresión Génica/efectos de los fármacos , Receptores de Hormona Liberadora de Corticotropina/genética , Regulación hacia Arriba , Adenoma/metabolismo , Adenoma/patología , Animales , Arginina Vasopresina/farmacología , Northern Blotting , Dexametasona/farmacología , Relación Dosis-Respuesta a Droga , Glucocorticoides/farmacología , Humanos , Masculino , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Proteínas Recombinantes , Células Tumorales CultivadasRESUMEN
We evaluated the usefulness of a desmopressin (DDAVP) test in the diagnosis of ACTH-dependent Cushing's syndrome. After an intravenous injection of 5 microg DDAVP, plasma ACTH levels increased to more than 200% of the basal levels in 10 of 10 patients with Cushing's disease, but remained less than 150% in all of 11 normal subjects, 3 patients with Addison's disease, 5 cases of Cushing's disease in remission, and 3 patients with ectopic ACTH syndrome. Peak levels of plasma cortisol after the DDAVP stimulation were 159 +/- 14% in the patients with Cushing's disease, and less than 150% of the basal levels in the other 5 groups. We also found a case of Cushing's disease with periodicity which responded to DDAVP only in the active stage. In vitro studies revealed that DDAVP directly stimulates ACTH release from corticotropic adenoma cells through V1b but not V2 vasopressin receptors. In conclusion, the DDAVP stimulation test, i.e., determination of plasma ACTH levels after 5 microg DDAVP injection, seems useful for discriminating Cushing's disease from normality, and may serve to facilitate the differentiation between Cushing's disease and ectopic ACTH syndrome.
Asunto(s)
Pruebas de Función de la Corteza Suprarrenal/métodos , Hormona Adrenocorticotrópica/sangre , Síndrome de Cushing/diagnóstico , Desamino Arginina Vasopresina/farmacología , Fármacos Renales/farmacología , Adenoma/química , Adenoma/patología , Hormona Adrenocorticotrópica/efectos de los fármacos , Hormona Adrenocorticotrópica/metabolismo , Adulto , Estudios de Cohortes , Síndrome de Cushing/sangre , AMP Cíclico/metabolismo , Desamino Arginina Vasopresina/administración & dosificación , Femenino , Humanos , Hidrocortisona/sangre , Hidrocortisona/metabolismo , Inyecciones Intravenosas , Riñón/química , Riñón/patología , Masculino , Persona de Mediana Edad , Receptores de Vasopresinas/clasificación , Receptores de Vasopresinas/genética , Valores de Referencia , Fármacos Renales/administración & dosificación , Sensibilidad y Especificidad , Factores de TiempoRESUMEN
To assess whether the cAMP-dependent protein kinase-A and/or the diacylglycerol-dependent protein kinase C (PKC) pathways play important roles in the activation of CRF neurons in vivo under physiological conditions, we tested the effect of microinjection of 8-bromo-cAMP (8-Br-cAMP) or 12-O-tetradecanoyl phorbol 13-acetate (TPA) into both paraventricular nuclei (PVN) of the hypothalamus in conscious rats. Both 8-Br-cAMP and TPA increased plasma ACTH concentrations and the POMC messenger RNA (mRNA) concentrations in the anterior pituitary. While injection of 8-Br-cAMP also increased CRF mRNA concentrations in hypothalamic tissue containing the PVN, TPA injection had no effect on CRF mRNA concentrations there. During insulin-induced hypoglycemia, which stimulates CRF gene expression and release, c-fos and c-jun mRNA increases in the hypothalamic tissue preceded the increase in the CRF mRNA level after insulin-induced hypoglycemia. Antisense oligodeoxyribonucleotides (oligos) directed against c-fos, c-jun, or the cAMP response element binding protein (CREB) mRNA were injected into both PVN before insulin-induced hypoglycemia to assess whether activator protein-1 or CREB mediates transcriptional activation of CRF during hypoglycemia. Only antisense oligo against CREB mRNA reduced the CRF mRNA level after insulin-induced hypoglycemia. These results suggest that protein kinase A may transduce intracellular signals in CRF neurons under physiological conditions and raises the possibility that CREB may be involved in stress-induced CRF gene expression.
Asunto(s)
Hormona Liberadora de Corticotropina/genética , Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , AMP Cíclico/farmacología , Expresión Génica , Hipotálamo/metabolismo , 8-Bromo Monofosfato de Adenosina Cíclica/administración & dosificación , 8-Bromo Monofosfato de Adenosina Cíclica/farmacología , Hormona Adrenocorticotrópica/sangre , Animales , Secuencia de Bases , Expresión Génica/efectos de los fármacos , Genes fos/genética , Genes jun/genética , Hipoglucemia/inducido químicamente , Hipoglucemia/metabolismo , Hipotálamo/efectos de los fármacos , Insulina , Masculino , Microinyecciones , Datos de Secuencia Molecular , Oligonucleótidos Antisentido/farmacología , Núcleo Hipotalámico Paraventricular/efectos de los fármacos , Núcleo Hipotalámico Paraventricular/metabolismo , Proopiomelanocortina/genética , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Acetato de Tetradecanoilforbol/farmacologíaRESUMEN
Adrenalectomy (ADX) leads to a decrease in the number of CRF-binding sites in the rat anterior pituitary (AP). However, the molecular mechanisms of CRF receptor (CRF-R) regulation are unknown. In the present study, we analyzed the effects of ADX on pituitary CRF-R1 messenger RNA (mRNA) levels in vivo and the direct effects of CRF, arginine vasopressin (AVP), and glucocorticoid, the levels of which are altered by ADX, on CRF-R1 mRNA levels in vitro. The mRNA level was determined by Northern blot analysis using a rat brain CRF-R1 complementary RNA probe. The CRF-R1 level in AP fell to 20% of the sham level 1 day after ADX and returned to the sham level after 14 days. In cultured rat AP cells, treatment with CRF, AVP, and dexamethasone led to significant reductions in CRF-R1 mRNA, with maximal inhibition to 32%, 22%, and 37% of control levels, respectively. The time course of CRF-R1 mRNA reduction varied depending on the drug, with effects detectable as early as 1 h after treatment. These findings indicate that elevated portal CRF and AVP levels may contribute to the decrease in CRF-R1 mRNA soon after ADX. A decrease in mRNA levels, in turn, may lead to a decrease in CRF-R1 protein on corticotrophs.
Asunto(s)
Regulación de la Expresión Génica , Adenohipófisis/metabolismo , ARN Mensajero/metabolismo , Receptores de Hormona Liberadora de Corticotropina/genética , Adrenalectomía , Hormona Adrenocorticotrópica/sangre , Animales , Arginina Vasopresina/farmacología , Secuencia de Bases , Células Cultivadas , Hormona Liberadora de Corticotropina/farmacología , Dexametasona/farmacología , Cinética , Masculino , Datos de Secuencia Molecular , Ratas , Ratas WistarRESUMEN
To examine the physiological role of cholinergic input in the regulation of CRF neurons in the paraventricular nucleus (PVN) of the hypothalamus, acetylcholine (ACh) was microinjected bilaterally into the dorsolateral border of the PVN of conscious rats. Changes in the levels of POMC messenger RNA (mRNA) in the anterior pituitary, CRF mRNA in hypothalamic tissue containing the PVN, and plasma ACTH were assessed. Plasma ACTH concentrations increased in a dose-dependent manner after ACh injection (1-100 pmol/side), reaching a peak 30 min after ACh injection and returning to baseline within 120 min. The POMC mRNA level in the anterior pituitary and the hypothalamic CRF mRNA level increased in a dose-dependent manner 120 min after ACh (0.1-10 pmol/side) injection. Intracerebroventricular pretreatment with atropine completely abolished the ACh-induced increase in plasma ACTH concentrations, whereas pretreatment with hexamethonium was without significant effect. The intracerebroventricular injection of ACh also increased plasma ACTH concentrations in a dose-dependent manner in conscious rats, but not in pentobarbital-anesthetized animals. Thus, cholinergic hypothalamic input stimulates CRF gene expression in the PVN and CRF secretion into the portal circulation under physiological conditions. The use of conscious animals is essential in elucidating the physiological roles of neurotransmitters and other modulators regulating CRF neurons.
Asunto(s)
Acetilcolina/farmacología , Hormona Liberadora de Corticotropina/genética , Expresión Génica/efectos de los fármacos , Núcleo Hipotalámico Paraventricular/metabolismo , Acetilcolina/administración & dosificación , Hormona Adrenocorticotrópica/sangre , Animales , Atropina/farmacología , Northern Blotting , Antagonistas Colinérgicos , Relación Dosis-Respuesta a Droga , Hexametonio/farmacología , Cinética , Masculino , Microinyecciones , Parasimpatolíticos/farmacología , Núcleo Hipotalámico Paraventricular/efectos de los fármacos , Adenohipófisis/metabolismo , Proopiomelanocortina/genética , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Receptores Colinérgicos/fisiologíaRESUMEN
Saiko agents, Chinese herbal drugs, stimulate corticotropin-releasing factor (CRF) release from the hypothalamus, adrenocorticotropin (ACTH) secretion and proopiomelanocortin (the precursor for ACTH) gene expression in the anterior pituitary. In the present study, the effect of intracerebroventricular injection of saikosaponin (SS)-a and -d, two of the main components of saiko agents, on hypothalamic CRF gene expression was examined in pentobarbital-anesthetized rats. Administration of SS-d, 0.2-2.0 micrograms/kg body wt, increased plasma ACTH levels, proopiomelanocortin mRNA levels in the anterior pituitary and the CRF mRNA level in the hypothalamus in a dose-dependent manner, whereas SS-a failed to have an affect on these levels. These findings indicate that SS-d stimulates both CRF gene expression and CRF release, which in turn increases ACTH release and proopiomelanocortin gene expression in the anterior pituitary. Therefore, SS-d is believed to have an important role both in saiko agent-induced CRF release and CRF gene expression in the hypothalamus.
Asunto(s)
Encéfalo/fisiología , Hormona Liberadora de Corticotropina/genética , Hipotálamo/metabolismo , Ácido Oleanólico/análogos & derivados , ARN Mensajero/metabolismo , Sapogeninas/farmacología , Saponinas , Hormona Adrenocorticotrópica/sangre , Animales , Inyecciones Intraventriculares , Masculino , Adenohipófisis/metabolismo , Proopiomelanocortina/genética , Ratas , Ratas WistarRESUMEN
Inhibin and activin are known to be involved in the pituitary hormone secretion as well as proliferation of the pituitary. We studied the expression of inhibin alpha, and beta A subunit and activin type II receptor (ACTR 2) mRNAs in human pituitary adenomas to determine the significance of inhibin and activin in pituitary hormone secretion. Tumor tissues were homogenized immediately after resection in guanidinium thiocyanate to extract total RNA. PCR was performed with reversely transcripted cDNA and respective amplification primers. DNA bands obtained for inhibin alpha, beta A and ACTR 2 by agarose gel-electrophoresis were 367, 285, and 389 bp, respectively. Messenger RNAs for inhibin beta A were demonstrated in all of the pituitary tissues studied, namely in 3 GH, 2 ACTH, 6 PRL and 1 FSH producing adenomas and 17 non-functioning adenomas. Inhibin alpha mRNAs were detected in 10 of 12 functioning adenomas and 15 of 17 non-functioning adenomas. ACTR 2 mRNAs were found in 11 out of 17 non-functioning adenomas, but only found in 3 out of 12 functioning adenomas. These results suggested local production of activin, a homodimer of beta-subunits, and inhibin, a heterodimer of alpha and beta subunits, in most of the pituitary adenomas regardless of their hormone secretion. On the other hand, a significantly higher incidence of ACTR 2 in non-functioning adenomas than in functioning adenomas suggested that activin had its main site of action in non-functioning adenomas, which could be potential gonadotropinomas.
Asunto(s)
Adenoma/metabolismo , Inhibinas/metabolismo , Neoplasias Hipofisarias/metabolismo , ARN Mensajero/metabolismo , Receptores de Factores de Crecimiento/metabolismo , Receptores de Activinas , Adulto , Anciano , Secuencia de Bases , Electroforesis en Gel de Agar , Femenino , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Hormonas Hipofisarias/metabolismo , Reacción en Cadena de la PolimerasaRESUMEN
To examine the physiological effects of norepinephrine (NE) in the paraventricular nucleus of the hypothalamus (PVH) on CRF gene expression and CRF release, NE was microinjected bilaterally into the PVH of conscious rats, and kinetic studies were performed on the levels of POMC messenger RNA (mRNA) in the anterior pituitary (AP), CRF mRNA in the PVH-containing hypothalamic fragment, and plasma ACTH. Plasma ACTH levels were increased dose dependently by NE (5-50 nmol/side) injection into the PVH. They reached their peaks after 30 min and returned to the basal values after 90 min. The POMC mRNA level in the AP and hypothalamic CRF mRNA level increased significantly 90 min after NE injection and increased further after 120 min. The POMC mRNA level in the AP and hypothalamic CRF mRNA level were increased dose dependently by NE (5-50 nmol/side) after 120 min. Intracerebroventricular pretreatment with prazosin abolished completely the increase in plasma ACTH levels after intrahypothalamic NE injection, whereas pretreatment with propranolol was without significant effect. These results suggest that NE stimulates CRF gene expression in the PVH and CRF secretion into the portal circulation, thus regulating positively the hypothalamic-pituitary-adrenal axis. alpha 1-Adrenergic receptors may mediate the action of NE on CRF neurons.
Asunto(s)
Estado de Conciencia/fisiología , Hormona Liberadora de Corticotropina/genética , Norepinefrina/farmacología , Núcleo Hipotalámico Paraventricular/fisiología , Hormona Adrenocorticotrópica/sangre , Animales , Hormona Liberadora de Corticotropina/análisis , Hormona Liberadora de Corticotropina/metabolismo , Relación Dosis-Respuesta a Droga , Regulación de la Expresión Génica , Sistema Hipotálamo-Hipofisario/fisiología , Masculino , Microinyecciones , Núcleo Hipotalámico Paraventricular/química , Núcleo Hipotalámico Paraventricular/metabolismo , Adenohipófisis/química , Adenohipófisis/metabolismo , Sistema Hipófiso-Suprarrenal/fisiología , Proopiomelanocortina/análisis , Proopiomelanocortina/genética , ARN Mensajero/análisis , ARN Mensajero/genética , Ratas , Ratas Wistar , Factores de TiempoRESUMEN
To determine if there is a short negative feedback effect of hypothalamic ACTH-related peptides on corticotropin-releasing factor (CRF) release in vivo, we examined the effect of cerebroventricular injection of alpha-melanocyte-stimulating hormone (alpha MSH) on ACTH levels in plasma and the anterior pituitary and CRF levels in the median eminence of the hypothalamus in adrenalectomized or sham-operated rats under pentobarbital anesthesia. alpha MSH did not affect basal ACTH or CRF levels in sham operated rats. However, elevated plasma ACTH levels and CRF levels in the median eminence were decreased by central administration of alpha MSH in adrenalectomized rats. These results suggest that there is a short negative feedback effect of alpha MSH on CRF release and it appears only in the absence of a long negative feedback effect of glucocorticoids.
Asunto(s)
Adrenalectomía , Hormona Liberadora de Corticotropina/metabolismo , alfa-MSH/farmacología , Hormona Adrenocorticotrópica/sangre , Hormona Adrenocorticotrópica/metabolismo , Animales , Hormona Liberadora de Corticotropina/sangre , Retroalimentación/fisiología , Inyecciones Intraventriculares , Masculino , Eminencia Media/efectos de los fármacos , Eminencia Media/metabolismo , Adenohipófisis/efectos de los fármacos , Adenohipófisis/metabolismo , Radioinmunoensayo , Ratas , Ratas Wistar , alfa-MSH/administración & dosificaciónRESUMEN
To differentiate between ectopic ACTH syndrome and Cushing's disease, gene expression of corticotropin-releasing hormone (CRH), proopiomelanocortin (POMC), and glucocorticoid receptor was examined in 10 pituitary adenomas (Cushing's disease) and in 10 ectopic ACTH-producing tumors. CRH increased plasma ACTH levels in all patients with Cushing's disease and in five patients with ectopic ACTH syndrome whose tumors contained CRH and CRH mRNA. In five CRH nonresponders, CRH was not detected in tumors that contained no CRH mRNA or that contained only long-size CRH mRNA. Dexamethasone (Dex) decreased plasma ACTH levels in all patients with Cushing's disease and in three patients with ectopic ACTH-producing bronchial carcinoid. These tumors contained glucocorticoid receptor mRNA. CRH increased and Dex decreased ACTH release and POMC mRNA levels in pituitary adenoma and bronchial carcinoid cells. PMA increased POMC mRNA levels only in carcinoid cells. These results reveal characteristics of ectopic ACTH-producing tumors: long-size CRH mRNA and PMA-induced POMC gene expression. In addition, there are two ectopic ACTH syndrome subtypes: tumors containing ACTH with CRH (CRH responder) and tumors without CRH. Dex decreases ACTH release and POMC mRNA levels in some bronchial carcinoids. Therefore, CRH and Dex tests have limited usefulness in differentiating between Cushing's disease and ectopic ACTH syndrome.
Asunto(s)
Adenoma/metabolismo , Hormona Liberadora de Corticotropina/biosíntesis , Síndrome de Cushing/metabolismo , Expresión Génica , Neoplasias Hipofisarias/metabolismo , Proopiomelanocortina/biosíntesis , Receptores de Glucocorticoides/biosíntesis , 8-Bromo Monofosfato de Adenosina Cíclica/farmacología , Adenoma/cirugía , Hormona Adrenocorticotrópica/sangre , Adulto , Anciano , Arginina Vasopresina/farmacología , Neoplasias de la Mama/sangre , Hormona Liberadora de Corticotropina/sangre , Hormona Liberadora de Corticotropina/farmacología , Dexametasona/farmacología , Neoplasias Esofágicas/sangre , Femenino , Humanos , Hidrocortisona/sangre , Neoplasias Pulmonares/sangre , Neoplasias Pulmonares/metabolismo , Masculino , Metirapona , Persona de Mediana Edad , Neoplasias Hipofisarias/cirugía , ARN Mensajero/biosíntesis , Acetato de Tetradecanoilforbol/farmacologíaRESUMEN
Administration of Saireito, a Saiko agent (a Chinese herbal drug), via a stomach cannula stimulates ACTH release and proopiomelanocortin, the precursor for ACTH, gene expression in the rat anterior pituitary. To study whether Saireito-stimulated secretion and synthesis of ACTH are mediated by hypothalamic corticotropin-releasing factor (CRF), we examined the effect of passive immunization of endogenous CRF by i.v. administration of CRF antiserum on Saireito-increased plasma ACTH levels and proopiomelanocortin gene expression in the rat anterior pituitary, under pentobarbital anesthesia. CRF antiserum inhibited Saireito-induced plasma ACTH levels and proopiomelanocortin mRNA levels in the anterior pituitary. This result indicates that Saireito stimulates CRF neurons to increase CRF release, which stimulates secretion and synthesis of ACTH.
Asunto(s)
Hormona Adrenocorticotrópica/biosíntesis , Hormona Adrenocorticotrópica/metabolismo , Hormona Liberadora de Corticotropina/fisiología , Medicamentos Herbarios Chinos/farmacología , Hipotálamo/fisiología , Hipófisis/metabolismo , Animales , Expresión Génica/efectos de los fármacos , Masculino , Hipófisis/efectos de los fármacos , Proopiomelanocortina/biosíntesis , Proopiomelanocortina/genética , Ratas , Ratas Wistar , Estimulación QuímicaRESUMEN
The effect of administration of Saireito, a Saiko agent, via a stomach cannula on adrenocorticotropin (ACTH) release and gene expression of proopiomelanocortin (POMC), the precursor for ACTH, in the anterior pituitary, as well as on the corticotropin-releasing factor (CRF) in the hypothalamus, was examined in pentobarbital anesthetized rats. Saireito decreased the hypothalamic CRF level due to an early release of CRF and stimulated ACTH release and POMC gene expression but did not increase CRF gene expression. These results suggest that Saireito does not stimulate CRF gene expression, although it does stimulate CRF release, which in turn stimulates POMC gene expression in the anterior pituitary and ACTH release.
Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Expresión Génica/efectos de los fármacos , Adenohipófisis/efectos de los fármacos , Proopiomelanocortina/biosíntesis , Hormona Adrenocorticotrópica/sangre , Animales , Northern Blotting , Hormona Liberadora de Corticotropina/sangre , Técnicas In Vitro , Masculino , Núcleo Hipotalámico Paraventricular/efectos de los fármacos , Núcleo Hipotalámico Paraventricular/metabolismo , Proopiomelanocortina/genética , ARN Mensajero/biosíntesis , Ratas , Ratas WistarRESUMEN
Neuropeptide Y (NPY) has a stimulatory effect on adrenocorticotropin (ACTH) and corticotropin-releasing factor (CRF) release. In the present study, to investigate the effect of NPY on CRF synthesis, the effect of centrally administered NPY on CRF messenger RNA (mRNA) levels in rat hypothalamus was examined under pentobarbital anesthesia. The administration of 0.01, 0.1 and 1 nmol of NPY into the lateral ventricle dose-dependently Increased the plasma ACTH levels, as well as the levels of proopiomelanocortin mRNA in the anterior pituitary. The CRF mRNA level in the hypothalamus also increased after administration of 0.1 and 1 nmol of NPY in a dose-dependent manner. The administration of 3 nmol of phentolamine or propranolol failed to block 0.1 nmol NPY-induced ACTH release or 1 nmol NPY-stimulated CRF mRNA levels in the hypothalamus. These results Indicate that the central administration of NPY increases the CRF mRNA levels in the hypothalamus and the probable CRF release, which increases the proopiomelanocortin mRNA levels and ACTH secretion in the anterior pituitary. Therefore, NPY seems to play a physiological role in the regulation of the release and synthesis of CRF in the hypothalamus.
Asunto(s)
Hormona Liberadora de Corticotropina/genética , Hipotálamo/metabolismo , Neuropéptido Y/fisiología , ARN Mensajero/metabolismo , Hormona Adrenocorticotrópica/metabolismo , Animales , Expresión Génica/efectos de los fármacos , Hipotálamo/efectos de los fármacos , Inyecciones Intraventriculares , Masculino , Neuropéptido Y/administración & dosificación , Fentolamina/farmacología , Adenohipófisis/efectos de los fármacos , Adenohipófisis/metabolismo , Proopiomelanocortina/genética , Propranolol/farmacología , Ratas , Ratas WistarRESUMEN
In this study, we examined the effect of passive immunization of endogenous corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) on hypoglycemia-induced adrenocorticotropic hormone (ACTH) secretion and determined proopiomelanocortin messenger RNA (POMC mRNA) levels in the anterior pituitary as well as hypothalamic CRF mRNA levels in pentobarbital anesthetized rats. The response of plasma ACTH to hypoglycemia was partially inhibited by the administration of CRF-antiserum (CRF-As) or AVP-antiserum (AVP-As) alone, but was found to be completely abolished by the administration of CRF-As + AVP-As as compared to the response in normal rabbit serum-treated rats. The hypoglycemia-induced POMC mRNA level in the anterior pituitary was completely inhibited by the administration of CRF-As alone and CRF-As + AVP-As, but was not inhibited by AVP-As alone as compared to the response in normal rabbit serum-treated rats. The administration of CRF-As and/or AVP-As did not affect hypoglycemia-induced CRF mRNA levels in the hypothalamus. These results indicate that the synergistic effect of CRF and AVP is important for hypoglycemia-induced ACTH secretion, but CRF is essential and indispensable for hypoglycemia-induced POMC gene expression in the anterior pituitary (AP).
Asunto(s)
Hormona Liberadora de Corticotropina/fisiología , Hipoglucemia/metabolismo , Adenohipófisis/metabolismo , Proopiomelanocortina/biosíntesis , Vasopresinas/fisiología , Animales , Arginina Vasopresina/biosíntesis , Glucemia/metabolismo , Northern Blotting , Hipotálamo/metabolismo , Inmunoglobulina G/metabolismo , Masculino , Proopiomelanocortina/genética , ARN Mensajero/biosíntesis , Radioinmunoensayo , Ratas , Ratas EndogámicasRESUMEN
Endogenous opioid peptides have a role in the regulation of the hypothalamic-pituitary-adrenal axis. Recently, beta-endorphin (EP) has been thought to inhibit CRF release in vivo and in vitro. In the present study we examined the effects of central administration of EP on ACTH secretion and gene expression of both CRF in the hypothalamus and POMC in the anterior pituitary gland (AP) during basal and insulin-induced hypoglycemia in pentobarbital-anesthetized rats. Administration of EP in the lateral ventricle decreased basal CRF levels in the median eminence and inhibited basal and hypoglycemia-induced ACTH secretion in a dose-dependent manner. Hypoglycemia-induced POMC mRNA levels in the AP and CRF mRNA levels in the hypothalamus were also dose-dependently inhibited by the administration of EP. The inhibitory effect of EP was reversed by naloxone. These results suggest that 1) central administration of EP acts through the opioid receptor to inhibit hypoglycemia-induced CRF gene expression in the hypothalamus and CRF release, which results in a decrease in ACTH secretion and POMC mRNA levels in the AP; and 2) the active site of EP is the CRF neuron in the paraventricular nucleus.